Navigation Links
Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations
Date:12/15/2009

at no other breast cancer test has demonstrated the reproducible clinical utility that Genomic Health has established with Oncotype DX, the company's plan to continue to add value to its breast cancer test through ongoing research and clinical experience, the belief that using Oncotype DX can predict chemotherapy benefit in women with ER+, N+ disease, the belief that Oncotype DX frequently changes treatment recommendations with an overall reduction in chemotherapy, the belief that Oncotype DX may have a potential role in neoadjuvant treatment planning and the company's plans regarding additional studies in this regard, the belief that certain study results provide a rationale for evaluating currently available and investigational agents that target certain pathways, the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization, and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc.
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
2. New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
3. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
5. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
6. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
7. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
8. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
9. Curemark CEO Presents at Epigenomics Conference
10. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
11. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Zebra Imaging, ... visualization technologies announced today a strategic partnership with ... in high-end 3D anatomy and biomedical models for ... and medical education markets.  Zygote maintains the world,s ... biomedical models and has pioneered development of high-end ...
(Date:10/31/2014)... JERUSALEM , October 31, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... the company will host a conference call to ... clinical trial of ORMD-0801, the company,s proprietary oral ... Monday, November 3, 2014 at 10:00 a.m. Eastern ...
(Date:10/31/2014)... 31, 2014  Zacks.com announces the list of stocks featured in ... the latest news and events impacting stocks and the financial markets. ... AMGN - Free Report ), Celgene (Nasdaq: CELG ... - Free Report ), Market Vectors Biotech ETF (AMEX: ... ETF (AMEX: XBI - Free Report ). ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... Oritavancin Studies Presented at ECCMID/ICC, MUNICH, Germany, ... announced results from two studies showing the,improved ... in vitro,when tested with a common wetting ... activity of oritavancin against S.,pneumoniae in a ...
... 04, 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that ... that its Data Monitoring Committee's (DMC),review of ... for patients with newly diagnosed multiple myeloma ... dose of dexamethasone (Decadron) in,combination with lenalidomide ...
Cached Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... 2014 The Suspension Revolution review published ... was developed by Dan Long, a suspension training specialist. ... fitness professional and life coach. The author of this ... muscles is not impossible , The Suspension Revolution review ... Suspension training promises efficiency when it comes to burning ...
(Date:10/31/2014)... October 31, 2014 North Shore Eye ... Garden City, Long Island and the addition of leading ... staff, according to North Shore Eye Care Medical Director, ... Acting Chairman of the Department of Ophthalmology of Winthrop-University ... in Garden City for more than 30 years. He ...
(Date:10/31/2014)... Beach, Florida (PRWEB) October 31, 2014 ... or, the “Company”) today announced it has signed a ... Canada-based companies in the urban cultivation sector - Urban ... (BC Northern Lights”), and W3 Metal Inc. (“W3 Metal” ... the “Target Companies”). Pursuant to the LOI and ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... cancer of the eye need not have to remove their ... The results of the Collaborative ocular Melanoma ... found that survival rates were the same regardless of whether ... radiation therapy.// , Davidorf, Professor ...
... affects women in their 30s and 40s, especially women.The illness ... cause pain, inflammation and joint destruction. , ... condition, but one third of the patients discontinue treatment early ... taking Methotrexate are prone for their drug-related liver damage .This ...
... exercise can improve their health or it would not make a ... Consensus statements published by the American College of ... researchers often can't tell how much health-improvement pay-off will result from ... make a difference at all. , , ...
... levels is becoming an increasingly important part of a medical ... or 'good' cholesterol) levels should be high, and low density ... At Johns Hopkins ... to measure non-HDL cholesterol too. This is the difference between ...
... to kill the deadly Hepatitis E virus has been designed by ... would kill the virus by cutting RNA. , , ... animals. The cloned virus could also be used for diagnostic purposes ... For this, the team had produced ...
... in tomato products, such as tomato sauce and ketchup, have ... especially prostate cancer, but the reason for such an action ... that lycopene, which is found in tomato products and other ... and treating the disease in its earliest stages.// ...
Cached Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... L.E.D. is mounted coaxially on the loupe ... battery pack giving 4 hours continuous use. ... and a charging unit that can hold ... as being a convenient container to keep ...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Inquire...
Medicine Products: